The success of SMA type 1 gene therapy was extended to SMA patients ≥6 months to <5 years with three copies of SMN2, and eligibility required the ability to sit independently in the absence of walking without support. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.